Eli Lilly and Company completed its acquisition of AtaiBeckley Inc. on Sept. 11, 2026, after AtaiBeckley shareholders approved the transaction at a special meeting. AtaiBeckley is now a wholly owned Lilly subsidiary. Shareholders received $6.75 in cash and one nontransferable contingent value right per share, with additional payments of up to $2.50 per share tied to clinical and regulatory milestones. The immediate equity value was about $2.8 billion, while total consideration could reach $3.8 billion. The milestones cover VLS-01 entering Phase 3 trials within four years, U.S. approval and DEA rescheduling of BPL-003 within five years, and U.S. approval and DEA rescheduling of VLS-01 within seven years. AtaiBeckley shares closed at $7.35, after rising about 80% in the six months before closing, while Lilly shares ended the day down 0.33% at $1,119.26. Lilly is acquiring a rapid-acting neuroplastogen pipeline led by BPL-003 for treatment-resistant depression. Carole Ho said the deal supports a shift away from chronic dosing toward faster-acting treatments for patients who respond inadequately to existing therapies. AtaiBeckley notified Nasdaq of the completed merger, requested a trading suspension and asked Nasdaq to file Form 25 to begin delisting procedures; it intends to file Form 15 to terminate its SEC reporting obligations.